Competitive Advantages
- High affinity and selectivity to Atrial Natriuretic Peptide
- Disrupts ANP-NPRA signaling
- Inhibits tumor burden and metastasis
Summary
Our scientists have developed a synthetic neutralizing antibody to ANP which has high selectivity and affinity for ANP and can be used to regulate ANP levels and attenuate NPRA binding to ANP in cancer cells. These antibodies can be integrated into polymers that may also be used to form nanoparticles. This technology provides a novel route to treating various forms of cancer.
Schematic for the Preparation MIPNPs
Desired Partnerships
- License
- Sponsored Research
- Co-development